21.27
price up icon4.01%   0.82
 
loading
前日終値:
$20.45
開ける:
$20.8
24時間の取引高:
898.76K
Relative Volume:
0.80
時価総額:
$3.61B
収益:
-
当期純損益:
$-323.01M
株価収益率:
-9.5811
EPS:
-2.22
ネットキャッシュフロー:
$-272.30M
1週間 パフォーマンス:
+4.62%
1か月 パフォーマンス:
-9.83%
6か月 パフォーマンス:
-34.47%
1年 パフォーマンス:
-41.73%
1日の値動き範囲:
Value
$20.80
$21.66
1週間の範囲:
Value
$20.40
$21.66
52週間の値動き範囲:
Value
$19.07
$39.55

Immunovant Inc Stock (IMVT) Company Profile

Name
名前
Immunovant Inc
Name
セクター
Healthcare (1169)
Name
電話
917-580-3099
Name
住所
320 WEST 37TH STREET, NEW YORK, NY
Name
職員
207
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
IMVT's Discussions on Twitter

IMVT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IMVT
Immunovant Inc
21.27 3.61B 0 -323.01M -272.30M -2.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-01-03 ダウングレード Wolfe Research Outperform → Peer Perform
2024-10-10 再開されました Raymond James Outperform
2024-10-09 繰り返されました Oppenheimer Outperform
2024-03-28 開始されました Oppenheimer Outperform
2024-03-13 開始されました Goldman Buy
2024-02-20 開始されました JP Morgan Overweight
2024-02-15 開始されました Wolfe Research Outperform
2023-12-12 開始されました Deutsche Bank Buy
2023-10-13 アップグレード UBS Neutral → Buy
2023-09-26 アップグレード Raymond James Mkt Perform → Outperform
2023-05-01 開始されました BofA Securities Buy
2023-04-25 開始されました Citigroup Buy
2023-03-31 開始されました Piper Sandler Overweight
2023-03-30 開始されました Stifel Buy
2023-02-15 開始されました Cantor Fitzgerald Overweight
2023-02-13 アップグレード Guggenheim Neutral → Buy
2023-01-03 アップグレード Wells Fargo Equal Weight → Overweight
2022-09-26 ダウングレード UBS Buy → Neutral
2021-12-08 開始されました Wells Fargo Equal Weight
2021-08-03 ダウングレード Robert W. Baird Outperform → Neutral
2021-08-02 ダウングレード Credit Suisse Neutral → Underperform
2021-06-01 ダウングレード Guggenheim Buy → Neutral
2021-06-01 ダウングレード Stifel Buy → Hold
2020-10-28 開始されました UBS Buy
2020-10-12 開始されました Guggenheim Buy
2020-10-08 開始されました Stifel Buy
2020-10-02 開始されました Credit Suisse Outperform
2020-08-26 繰り返されました H.C. Wainwright Buy
2020-08-25 開始されました Raymond James Outperform
2020-07-29 開始されました H.C. Wainwright Buy
2020-02-24 開始されました SVB Leerink Outperform
すべてを表示

Immunovant Inc (IMVT) 最新ニュース

pulisher
12:53 PM

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? - Insider Monkey

12:53 PM
pulisher
12:35 PM

Immunovant’s chief medical officer Macias sells $42,867 in stock By Investing.com - Investing.com Nigeria

12:35 PM
pulisher
Feb 21, 2025

Immunovant CEO Peter Salzmann sells $322,057 in stock to cover tax obligations - Investing.com

Feb 21, 2025
pulisher
Feb 21, 2025

Immunovant's chief medical officer Macias sells $42,867 in stock - Investing.com India

Feb 21, 2025
pulisher
Feb 21, 2025

Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 21, 2025
pulisher
Feb 19, 2025

12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 19, 2025
pulisher
Feb 19, 2025

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - MSN

Feb 19, 2025
pulisher
Feb 19, 2025

Biotech Kingpin: Why Insiders Are Betting Big on Immunovant - Reporteros del Sur -

Feb 19, 2025
pulisher
Feb 19, 2025

ABC Arbitrage SA Invests $734,000 in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Feb 19, 2025
pulisher
Feb 18, 2025

Banque Pictet & Cie SA Sells 13,440 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

(IMVT) Investment Analysis and Advice - Stock Traders Daily

Feb 17, 2025
pulisher
Feb 14, 2025

Immunovant Inc [IMVT] Shares Rise 3.33 % on Thursday - Knox Daily

Feb 14, 2025
pulisher
Feb 14, 2025

Guggenheim cuts Immunovant stock target to $44, maintains Buy - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Immunovant (NASDAQ:IMVT) Given New $44.00 Price Target at Guggenheim - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Immunovant's Key Batoclimab Trial Catalysts Expected By MarchCan The Stock Bounce Back? - RTTNews

Feb 13, 2025
pulisher
Feb 13, 2025

Immunovant FY2025 EPS Estimate Raised by Leerink Partnrs - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Immunovant stock hits 52-week low at $19.08 amid challenges By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 12, 2025

Immunovant stock hits 52-week low at $19.08 amid challenges - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq

Feb 12, 2025
pulisher
Feb 12, 2025

Immunovant (NASDAQ:IMVT) Hits New 12-Month Low After Earnings Miss - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by abrdn plc - MarketBeat

Feb 12, 2025
pulisher
Feb 11, 2025

Guggenheim cuts Immunovant stock target to $44, maintains Buy By Investing.com - Investing.com Australia

Feb 11, 2025
pulisher
Feb 11, 2025

IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

Immunovant (NASDAQ:IMVT) Price Target Cut to $44.00 by Analysts at Guggenheim - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Immunovant (NASDAQ:IMVT) Reaches New 12-Month Low on Disappointing Earnings - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Immunovant’s (IMVT) Buy Rating Reiterated at HC Wainwright - Defense World

Feb 10, 2025
pulisher
Feb 10, 2025

Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Analysts - Defense World

Feb 10, 2025
pulisher
Feb 10, 2025

Oppenheimer Adjusts Price Target on Immunovant to $54 From $53, Keeps Outperform Rating - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Immunovant (NASDAQ:IMVT) Issues Quarterly Earnings Results - MarketBeat

Feb 10, 2025
pulisher
Feb 09, 2025

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Immunovant (NASDAQ:IMVT) Shares Down 5% Following Weak Earnings - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

HC Wainwright Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT) - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

Immunovant Inc [NASDAQ: IMVT] Sees Decrease in Stock Value - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

IMVT’s Market Whiplash: -17.80% YTD Decline, -17.34% Plunge in 30 Days - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Immunovant (NASDAQ:IMVT) Stock Price Down 5% on Disappointing Earnings - Defense World

Feb 07, 2025
pulisher
Feb 06, 2025

Immunovant Reports Progress Amid Increased R&D Costs - TipRanks

Feb 06, 2025
pulisher
Feb 06, 2025

Immunovant (NASDAQ:IMVT) Sets New 1-Year LowHere's What Happened - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Immunovant's Fiscal Q3 Loss Widens -February 06, 2025 at 07:40 am EST - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

Immunovant Inc. (IMVT) reports earnings - Quartz

Feb 06, 2025
pulisher
Feb 06, 2025

Immunovant, Inc. SEC 10-Q Report - TradingView

Feb 06, 2025
pulisher
Feb 06, 2025

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - The Manila Times

Feb 06, 2025

Immunovant Inc (IMVT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Immunovant Inc (IMVT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Barnett Eva Renee
Chief Financial Officer
Feb 19 '25
Sale
20.86
2,814
58,700
321,952
Salzmann Peter
Chief Executive Officer
Feb 19 '25
Sale
20.86
15,439
322,058
948,786
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):